在HER2-呈阳性的乳腺癌中,新的治疗可减少疾病增加或死亡的风险44%。 New treatment cuts risk of disease progression or death in HER2-positive breast cancer by 44%.

一项新的研究表明,与目前的标准治疗相比,T-DXd和pertuzumab相结合,大大降低了HER2-呈阳性的转移性乳腺癌患者的疾病增发或死亡风险。 A new study shows that a combination of T-DXd and pertuzumab significantly reduces the risk of disease progression or death in patients with HER2-positive metastatic breast cancer, compared to the current standard treatment. 这种形式的乳腺癌占病例的15-20%,但十多年来没有出现重大进步。 This form of breast cancer, which accounts for 15-20% of cases, hasn't seen major advancements in over a decade. 新治疗直接针对癌症细胞,将累进或死亡风险降低44%,将中位无累进存活率提高到40.7个月,而标准护理为26.9个月。 The new treatment, which targets cancer cells directly, reduced the risk of progression or death by 44% and improved median progression-free survival to 40.7 months, compared to 26.9 months with standard care. 这些调查结果可能导致新的一线疗法,预计将提交给世界各地的监管机构。 These findings could lead to a new first-line therapy and are expected to be submitted to regulators worldwide.